Annual Report

Overview

The report covers Mabpharm and its subsidiaries for 2022, with ESG governance assigned to the Board, Audit Committee and ESG Working Group. It reports 7,868.11 ton of Scope 1 and Scope 2 GHG emissions, 19,600.46 000'KWh of energy consumption and 95,274.56 m3 of water consumption. The workforce comprised 417 full-time employees, and the company reported zero work-related fatalities. It also highlights a RMB296,000 donation and approximately 2,000 free infliximab drugs for patients with autoimmune diseases.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services